Prevalence and treatment scale-up estimates.

HR, PWID in harm reduction programs; @, based on the population estimate from Tempalski et al [20]; IQR, interquartile range; A, data from the CDC-sponsored National HIV Behavioral Surveillance System (NHBS09) of 2009; B data from the Third Collaborative Injection Drug Users (CIDUS III) study; C was calculated using HRNAP~HABP *(1- ξδ) where ξ = 0.8 and δ = 0.26; D, based on empirical data of HCV-RNA and HCV-Ab measurements (see Methods) which translated into δ = 0.34 [25]; M, million; ** based on sensitivity analysis (S2–S6 Tables). *Note that sub-populations are overlapping (see Discussion). Prevalence and treatment scale-up estimates.